Ernexa Therapeutics Inc. (ERNA) Earnings History
Annual and quarterly earnings data from 2015 to 2025
Loading earnings history...
ERNA EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ERNA Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | 83.5% | -2693.1% | -7652.7% |
| 2023 | -247.1% | -31080.9% | -31864.7% |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export ERNA earnings history in CSV or JSON format
Free sign-in required to download data
Ernexa Therapeutics Inc. (ERNA) Earnings Overview
As of May 8, 2026, Ernexa Therapeutics Inc. (ERNA) reported trailing twelve-month net income of -$14M, reflecting -42.7% year-over-year growth. The company earned $-44.83 per diluted share over the past four quarters.
Looking at the long-term picture, ERNA's historical earnings data spans multiple years. The company achieved its highest annual net income of $12M in fiscal 2020.
Ernexa Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including FATE (-$136M net income, -2051.1% margin), CRSP (-$569M net income, -16569.8% margin), BEAM (-$65M net income, -57.2% margin), ERNA has comparable earnings metrics. Compare ERNA vs FATE →
ERNA Earnings vs Peers
Earnings metrics vs comparable public companies
ERNA Historical Earnings Data (2015–2025)
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$14M | +68.3% | -$9M | $-56.00 | - | - |
| 2024 | -$45M | -105.6% | -$16M | $-39.25 | -7652.7% | -2693.1% |
| 2023 | -$22M | +11.8% | -$21M | $-102.00 | -31864.7% | -31080.9% |
| 2022 | -$25M | +79.9% | -$33M | $-201.50 | - | - |
| 2021 | -$123M | -1129.3% | -$114M | $-1415.25 | - | - |
| 2020 | $12M | +681.6% | -$7M | $-87.75 | - | - |
| 2019 | -$2M | -690.3% | -$1M | $-712.00 | -10.3% | -6.1% |
| 2018 | $-259,000 | +76.0% | $464,000 | $-96.25 | -1.1% | 2.0% |
| 2017 | -$1M | +63.2% | -$1M | $-441.00 | -5.1% | -6.6% |
| 2016 | -$3M | +59.5% | -$2M | $-1536.00 | -13.1% | -10.2% |
See ERNA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ERNA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ERNA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonERNA — Frequently Asked Questions
Quick answers to the most common questions about buying ERNA stock.
Is ERNA growing earnings?
ERNA EPS fell to $-44.83, with earnings declining -42.7%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-14M.
What are ERNA's profit margins?
Ernexa Therapeutics Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are ERNA's earnings?
ERNA earnings data spans 2015-2025. The declining earnings trend is -42.7% YoY. Historical data enables comparison across business cycles.